The Food and Drug Administration yesterday announced changes to the prescribing information included in outpatient opioid pain medication labels to provide expanded guidance to health care professionals on how to safely decrease or discontinue these medications in patients who are physically dependent on them. The agency said it has received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased, a safety concern it continues to track.

Related News Articles

Chairperson's File
COVID-19 has been at the forefront for health care professionals, and for everyone, this year. And it looks like it will remain that way for some time. However…
Headline
Suicide deaths increased by 37% between 2000 and 2018, with 41 states experiencing statistically significant increases over the same period, according to a…
Headline
The National Academies of Sciences Engineering, and Medicine yesterday released recommendations for improving outcomes and metrics associated with four grant…
Headline
The Centers for Medicare & Medicaid Services recently announced a six-month delay in implementation of its Innovation Center Maternal Opioid Misuse (MOM)…
Headline
Mallinckrodt Pharmaceuticals today announced an agreement in principle on a settlement to resolve all opioid-related claims against the company in…
Headline
Public and private entities can apply for $1 million grants for a three-year period to enhance or expand opioid and other substance use disorder services in…